Frazier Life Sciences Management Portfolio
Growth & qualityFrazier Life Sciences Management, L.P. 13F holdings · Q3 2026 vs Q2 2026
Why growth & quality: 40 holdings, 12 effective · top 10 74% · turnover 13% a quarter · earnings yield -5.6% (median 2.9%) · 19 quarters of 13Fs
- 13F value
- $4.0bn−12.2% vs $4.6bn in Q2 2026
- Holdings
- 40 5 new · 2 sold out
- Top 10 weight
- 62.0% Largest: MIRM 16.3%
- Bought est.
- $454m New positions and adds
- Sold est.
- $322m Trims and exits
- Quarter
- Q3 2026 Filed
Largest trades since Q2 2026
Estimated dollars: the change in shares times the quarter-end price the filing implies. Exits use last quarter's value.
| Action | Stock | Shares | Est. traded | Weight | Other gurus |
|---|---|---|---|---|---|
| New | ATTOATTOVIA THERAPEUTICS INC | New | +$121m | 0.0% → 3.0% | 1 |
| Sold out | BBIOBRIDGEBIO PHARMA INC | −100.0% | −$115m | 2.5% → 0.0% | — |
| New | BRVEBRAVEHEART BIO INC | New | +$106m | 0.0% → 2.6% | 4 |
| Sold out | CYTKCYTOKINETICS INC | −100.0% | −$99m | 2.2% → 0.0% | — |
| Added | ERASERASCA INC | +18.0% | +$66m | 10.0% → 10.7% | 3 |
| Trimmed | SVRASAVARA INC | −88.5% | −$44m | 1.3% → 0.1% | 4 |
| Added | MNKDMANNKIND CORP | +138.7% | +$36m | 0.6% → 1.5% | 2 |
| Trimmed | KRYSKRYSTAL BIOTECH INC | −18.7% | −$30m | 3.9% → 3.2% | 2 |
| New | CLDXCELLDEX THERAPEUTICS INC NEW | New | +$29m | 0.0% → 0.7% | 3 |
| Trimmed | IRONDISC MEDICINE INC | −31.0% | −$27m | 2.2% → 1.5% | 6 |
| Added | ACRSACLARIS THERAPEUTICS INC | +77.2% | +$20m | 0.6% → 1.1% | 2 |
| New | SRPTSAREPTA THERAPEUTICS INC | New | +$19m | 0.0% → 0.5% | 2 |
| Added | PBLSPARABILIS MEDICINES INC | +21.3% | +$13m | 1.1% → 1.9% | 5 |
| Added | DYNDYNE THERAPEUTICS INC | +22.2% | +$11m | 1.5% → 1.5% | 5 |
| Added | IMCRIMMUNOCORE HLDGS PLC | +71.2% | +$10m | 0.3% → 0.6% | 4 |
| New | ORICORIC PHARMACEUTICALS INC | New | +$10m | 0.0% → 0.3% | 1 |
| Added | MAZEMAZE THERAPEUTICS INC | +5.0% | +$6.8m | 3.3% → 3.6% | 1 |
| Trimmed | TRVITREVI THERAPEUTICS INC | −4.0% | −$5.7m | 4.0% → 3.4% | 0 |
| Added | VORVOR BIOPHARMA INC | +7.9% | +$3.8m | 1.0% → 1.3% | 4 |
| Added | KLRAKAILERA THERAPEUTICS INC | +9.1% | +$1.1m | 0.5% → 0.3% | 2 |
| Trimmed | TARSTARSUS PHARMACEUTICALS INC | −1.1% | −$653k | 1.0% → 1.4% | 3 |
All holdings 40 identified, plus $523m in securities without a listed ticker
Click a column to sort. Values are as reported at quarter-end, not today's prices.
| # | Stock | Shares | ||||
|---|---|---|---|---|---|---|
| 1 | MIRMMIRUM PHARMACEUTICALS INC | $656m | 7,679,684 | Unchanged | 8 | |
| 2 | ERASERASCA INC | $432m | 29,475,188 | +18.0% | 3 | |
| 3 | MBXMBX BIOSCIENCES INC | $390m | 6,652,013 | Unchanged | 3 | |
| 4 | ARQTARCUTIS BIOTHERAPEUTICS INC | $261m | 9,874,511 | Unchanged | 2 | |
| 5 | MAZEMAZE THERAPEUTICS INC | $144m | 5,282,915 | +5.0% | 1 | |
| 6 | TRVITREVI THERAPEUTICS INC | $137m | 9,539,147 | −4.0% | — | |
| 7 | KRYSKRYSTAL BIOTECH INC | $130m | 391,319 | −18.7% | 2 | |
| 8 | PVLAPALVELLA THERAPEUTICS INC NE | $122m | 882,400 | Unchanged | 2 | |
| 9 | ATTOATTOVIA THERAPEUTICS INC | $121m | 7,046,271 | New | 1 | |
| 10 | BRVEBRAVEHEART BIO INC | $106m | 5,267,321 | New | 4 | |
| 11 | PHATPHATHOM PHARMACEUTICALS INC | $91m | 12,466,489 | Unchanged | 1 | |
| 12 | PBLSPARABILIS MEDICINES INC | $75m | 2,330,750 | +21.3% | 5 | |
| 13 | DYNDYNE THERAPEUTICS INC | $62m | 3,853,082 | +22.2% | 5 | |
| 14 | QUITACHIEVE LIFE SCIENCE INC | $62m | 7,614,836 | Unchanged | 4 | |
| 15 | MNKDMANNKIND CORP | $61m | 15,755,491 | +138.7% | 2 | |
| 16 | IRONDISC MEDICINE INC | $61m | 934,852 | −31.0% | 6 | |
| 17 | TARSTARSUS PHARMACEUTICALS INC | $57m | 720,338 | −1.1% | 3 | |
| 18 | VORVOR BIOPHARMA INC | $52m | 2,743,939 | +7.9% | 4 | |
| 19 | ZLABZAI LAB LTD | $50m | 1,902,320 | Unchanged | 4 | |
| 20 | ACRSACLARIS THERAPEUTICS INC | $46m | 8,729,516 | +77.2% | 2 | |
| 21 | AURAAURA BIOSCIENCES INC | $45m | 7,100,000 | Unchanged | 3 | |
| 22 | ALLOALLOGENE THERAPEUTICS INC | $36m | 22,446,668 | Unchanged | 1 | |
| 23 | BCRXBIOCRYST PHARMACEUTICALS INC | $33m | 4,009,240 | Unchanged | 4 | |
| 24 | CLDXCELLDEX THERAPEUTICS INC NEW | $29m | 900,080 | New | 3 | |
| 25 | ACADACADIA PHARMACEUTICALS INC | $29m | 1,438,198 | Unchanged | 2 | |
| 26 | STTKSHATTUCK LABS INC | $26m | 3,750,000 | Unchanged | 1 | |
| 27 | IMCRIMMUNOCORE HLDGS PLC | $25m | 829,752 | +71.2% | 4 | |
| 28 | DSGNDESIGN THERAPEUTICS INC | $23m | 1,809,854 | Unchanged | 1 | |
| 29 | EOLSEVOLUS INC | $21m | 2,630,665 | Unchanged | 1 | |
| 30 | SRPTSAREPTA THERAPEUTICS INC | $19m | 1,069,959 | New | 2 | |
| 31 | RLAYRELAY THERAPEUTICS INC | $18m | 1,015,693 | Unchanged | 3 | |
| 32 | LXEOLEXEO THERAPEUTICS INC | $16m | 4,824,725 | Unchanged | 4 | |
| 33 | VALNVALNEVA SE | $14m | 2,291,666 | Unchanged | — | |
| 34 | KLRAKAILERA THERAPEUTICS INC | $14m | 1,200,000 | +9.1% | 2 | |
| 35 | GLUEMONTE ROSA THERAPEUTICS INC | $12m | 1,000,000 | Unchanged | 4 | |
| 36 | ORICORIC PHARMACEUTICALS INC | $10m | 751,672 | New | 1 | |
| 37 | AUTLAUTOLUS THERAPEUTICS LTD | $8.6m | 4,447,910 | Unchanged | — | |
| 38 | SVRASAVARA INC | $5.7m | 1,113,752 | −88.5% | 4 | |
| 39 | XLOXILIO THERAPEUTICS INC | $3.8m | 422,505 | Unchanged | — | |
| 40 | IBIOIBIO INC | $2.3m | 1,953,467 | Unchanged | — |
Closest portfolios
Overlap is the weight two books have in common: for each shared stock, the smaller of the two weights, summed.
- TCG Crossover Management13.1%12 shared · MIRM, DYN, IRON, VOR
- Montanova Capital10.8%7 shared · ARQT, PVLA, AURA, LXEO
- Paradigm Biocapital Advisors9.5%6 shared · MBX, ERAS, TARS, QUIT
- Novo Holdings8.7%3 shared · MIRM, DYN, CLDX
- Rtw Investments7.9%11 shared · ERAS, TARS, ZLAB, ACAD
- Ra Capital Management6.2%9 shared · PBLS, IRON, VOR, ZLAB
- Bvf5.3%5 shared · PVLA, MIRM, IMCR, IRON
- Avoro Capital Advisors3.5%3 shared · KRYS, BRVE, LXEO
- Rubric Capital Management3.2%2 shared · ARQT, MNKD
- Deerfield Management2.6%5 shared · PBLS, BCRX, IRON, SVRA
Only here
The largest holdings no other tracked guru owns.
- TRVITREVI THERAPEUTICS INC3.4%
- VALNVALNEVA SE0.4%
- AUTLAUTOLUS THERAPEUTICS LTD0.2%
- XLOXILIO THERAPEUTICS INC0.1%
- IBIOIBIO INC0.1%
A 13F is a filing, not a live portfolio. It lists US-listed long stock positions at quarter-end, and it arrives up to 45 days later. Cash, shorts, bonds, options and foreign listings are not in it. Trade sizes here are estimates from the change in share count, restated for stock splits.
Snapshot refreshed